Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01386801
Other study ID # FIHC-2009-01
Secondary ID
Status Active, not recruiting
Phase N/A
First received June 30, 2011
Last updated September 5, 2013
Start date December 2009
Est. completion date June 2050

Study information

Verified date August 2013
Source Fairbanks Institute
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Blood samples and health information (e.g., age at diagnosis, test results) are collected for the purposes of genetic research. The blood samples are assigned a number and stored in a repository for safe keeping until they are needed for a research project. Participants are persons who are healthy (not having high blood pressure, diabetes, or high cholesterol levels) or persons who have Diabetes Mellitus Type II(T2D) and live in Indiana. Participants complete a questionnaire at the time the blood sample is drawn. Visits are repeated at 2 and 5 years after initial contact. Researchers apply to the Fairbanks Institute for use of the blood samples and health information minus participant names and contact information. Their research is required to be related to find genes or substances made by genes that may be involved in Diabetes Mellitus Type II with the purpose of improving the investigators understanding of the illness potentially leading to the development of new diagnostic tools for identifying the illness, new treatments,or preventative measures.


Description:

Study Aim:

The purpose of this study is to create an extensively annotated bio-repository platform for hypothesis-driven research that will lead to advancements in the diagnosis, treatment and prevention of diseases common to the population of Indiana. The second phase of this research platform will be created by collecting blood samples from two groups of individuals in the Central Indiana community, one with documented evidence of Diabetes Mellitus Type II(T2D), and a second group of age, gender and ethnicity matched individuals without clinical evidence of Diabetes. Each individual's blood sample will be linked to their clinical, demographic and epidemiological information, gathered both retrospectively and prospectively.

Recruitment:

This study will include 500 individuals with T2D (the T2D Group) and 500 individuals who are age, gender, and ethnicity matched to the T2D Group, but without presentation of clinical evidence of T2D (the Control Group). To reflect the growing representation of Hispanics in Central Indiana, Hispanics will be overly recruited in both groups so that the study population accurately reflects the general population of Central Indiana.

Follow-up:

As this is a prospective, longitudinal study, follow-up of study subjects is intended to include two follow up visit and continue indefinitely, unless, of course, at any time, consent for further follow-up is withdrawn by the subject. Follow-up will include visits at 2 and 5 years post initial contact and continuing access to the subject's medical record to pursue data concerning changes in the subject's health. Subjects may be contacted by telephone, mail or email every twelve months to ask if they wish to continue participation in the study. The 2 and 5 year follow up visits mirror the initial visit.

The collected dataset (made up of the collected blood samples linked to clinical and epidemiological information collected retrospectively and prospectively), will be used in medical research to find genes, or gene products such as RNA or proteins that will help in understanding the causes of disease and will guide the development of new treatments


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1000
Est. completion date June 2050
Est. primary completion date December 2049
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:T2D Group

Study subjects will be recruited for the T2D group based on a history confirmed by the medical record of at least one of the following:

- A fasting blood glucose of greater than or equal to 126 mg/dL on two separate occasions

- A random (non-fasting) blood glucose of greater than or equal to 200 mg/dL on two separate occasions

- A blood glucose of greater than 200 mg/dL at 2 hours during a standard oral glucose tolerance test

- A HgbA1c of greater than or equal to 6.5%

Females who are pregnant will be excluded.

Control Group

Study subjects for the Control Group will have:

- no confirmed history of T2D as defined above

- A fasting blood glucose of 100 mg/dL or less

Medical records will be obtained to ensure subjects meet study inclusion criteria.

Exclusion Criteria:Exclusion criteria for both the T2D Group and the Control Group are a known or reported history of:

- Hepatitis B

- Hepatitis C

- AIDS (HIV positive)

- Tuberculosis

- Cancer (including melanoma, but excluding low-malignancy skin cancer)

- Non-autologous bone marrow transplant

- Blood transfusion within 120 days

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Locations

Country Name City State
United States American Health Network Avon Indiana
United States Investigator's Research Group Brownsburg Indiana
United States American Health Network Franklin Indiana
United States American Health Network Greenfield Indiana
United States American Health Network Indianapolis Indiana
United States Krannert Cardiology Indianapolis Indiana
United States Oral Health Research Institute Indianapolis Indiana
United States IU School of Medicine/CTSI Indianapolis (Downtown) Indiana
United States Alivio Medical Center Indianapolis (Spanish speaking) Indiana
United States IU Medical Group Indianapolis (Spanish/English speaking) Indiana
United States American Health Network Muncie Indiana

Sponsors (5)

Lead Sponsor Collaborator
Fairbanks Institute BioCrossroads, Indiana University School of Medicine, Regenstrief Institute, Inc., Richard M. Fairbanks Foundation

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02261545 - The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient Phase 4
Completed NCT02028091 - Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements N/A
Completed NCT01684813 - VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel Phase 4
Completed NCT01252524 - Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study N/A
Recruiting NCT01311401 - Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel N/A
Completed NCT00563225 - 20 Week Bridging Study in Type II DM Phase 3
Recruiting NCT01565096 - Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy Phase 4
Completed NCT00151697 - LANN-study: Lantus, Amaryl, Novorapid, Novomix Study Phase 3
Withdrawn NCT01453751 - Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes N/A
Not yet recruiting NCT01775059 - Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4 N/A
Completed NCT01281098 - Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR. Phase 2
Completed NCT01669473 - A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use N/A
Completed NCT02036372 - Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus N/A
Completed NCT03258840 - EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus N/A
Completed NCT02144948 - Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II Phase 3